TMCnet News
Shareholder Alert: Robbins LLP Announces It Is Investigating Immunomedics, Inc. (IMMU) for Misleading ShareholdersShareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. (NASDAQ: IMMU) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is developing its antibody-drug conjugate IMMU-12. If you suffered a loss as a result of Immunomedics' misconduct, click here. Immunomedics, Inc. (IMMU) Drug Presentation Removed From ASCO Meeting
Immunomedics, Inc. (IMMU) Shareholders Have Legal Options
Contact us to learn more:
Want to be notified if a class action against Immunomedics settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005815/en/ |